Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type 1 (HIV-1) infection. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates. PRO 542 binds to the viral surface glycoprotein...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Jacobson, Jeffrey M., Israel, Robert J., Lowy, Israel, Ostrow, Nancy A., Vassilatos, Linda S., Barish, Melanie, Tran, Diep N. H., Sullivan, Brian M., Ketas, Thomas J., O'Neill, Tobias J., Nagashima, Kirsten A., Huang, Wei, Petropoulos, Christos J., Moore, John P., Maddon, Paul J., Olson, William C.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2004
Soggetti:	Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC321533/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14742190/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.2.423-429.2004
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!